Tvardi Therapeutics (TVRD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tvardi Therapeutics (TVRD) Healthcare & Pipeline Overview

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies targeting STAT3 for fibrosis-driven diseases. The company's lead candidate, TTI-101, is undergoing Phase 2 clinical trials, positioning Tvardi within the competitive biotechnology landscape focused on unmet medical needs.

What Is the Investment Thesis for TVRD?

Tvardi Therapeutics presents a notable research candidate due to its focus on STAT3 inhibition for fibrosis-driven diseases. The lead candidate, TTI-101, undergoing Phase 2 trials for IPF and HCC, addresses significant unmet medical needs. Positive clinical trial results could drive substantial value. With a market cap of $17.2M and a beta of 0.15, Tvardi offers a potentially high-reward, albeit risky, investment profile. Key value drivers include successful clinical trial outcomes, potential FDA approval for TTI-101, and expansion of the pipeline with additional STAT3-targeting therapies. Ongoing clinical trials represent potential catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

TVRD Key Highlights

Lead candidate TTI-101 is in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options.

• TTI-101 is also in Phase 2 clinical trials for hepatocellular carcinoma (HCC), a type of liver cancer with a high mortality rate.
• Tvardi Therapeutics focuses on oral small molecule therapies, offering a potentially more convenient administration route compared to existing injectable treatments.
• The company's therapeutic approach targets STAT3, a key signaling pathway implicated in fibrosis, inflammation, and cancer.
• Tvardi Therapeutics has a market capitalization of $17.2M, indicating its position as a smaller player in the biotechnology industry.

Who Are TVRD's Competitors?

TVRD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TVRD's Key Strengths?

Novel STAT3-targeting approach.

• Oral small molecule formulation.
• Phase 2 clinical trials underway.
• Experienced management team.

What Are TVRD's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources.
• High risk of clinical trial failure.
• Competition from established pharmaceutical companies.

What Could Drive TVRD Stock Higher?

Data readout from Phase 2 clinical trial of TTI-101 in IPF.

• Data readout from Phase 2 clinical trial of TTI-101 in HCC.
• Enrollment of patients in Phase 2 clinical trials.
• Expansion of pipeline with additional STAT3-targeting therapies.

What Are the Key Risks for TVRD?

Financial-distress signal — its Altman Z-Score of -13.11 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-64.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures.
• Regulatory hurdles.
• Competition from other therapies.
• Patent challenges.
• Dependence on successful development of TTI-101.

What Are the Growth Opportunities for TVRD?

• Expansion into Additional Fibrosis-Driven Diseases: Tvardi has the opportunity to expand its pipeline by developing STAT3-targeting therapies for other fibrosis-driven diseases, such as non-alcoholic steatohepatitis (NASH) and systemic sclerosis. Timeline: 2-3 years for preclinical development and initiation of Phase 1 trials.
• Strategic Partnerships and Collaborations: Tvardi can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. Collaborations can provide access to funding, expertise, and global distribution networks. This would allow Tvardi to focus on its core competencies in research and development. Timeline: Ongoing.
• Out-Licensing or Acquisition of TTI-101: Positive Phase 2 clinical trial results for TTI-101 could attract interest from larger pharmaceutical companies, leading to potential out-licensing agreements or an acquisition of the company. This would provide Tvardi with significant upfront payments, milestone payments, and royalties on future sales. Timeline: 1-2 years following Phase 2 data readout.
• Development of Companion Diagnostics: Tvardi can develop companion diagnostics to identify patients who are most likely to respond to TTI-101. This would improve the efficiency of clinical trials and increase the likelihood of regulatory approval. Companion diagnostics can also be used to personalize treatment and improve patient outcomes. Timeline: 2-3 years for development and validation.
• Geographic Expansion: Tvardi can expand its clinical trials and commercialization efforts to new geographic markets, such as Europe and Asia. These markets have a significant patient population with fibrosis-driven diseases and offer substantial growth potential. Timeline: 3-5 years for regulatory approval and market access.

What Are TVRD's Competitive Advantages?

• Proprietary STAT3-targeting technology.
• Lead candidate TTI-101 in Phase 2 clinical trials.
• Focus on oral small molecule therapies for convenient administration.
• Experienced management team with expertise in drug development.

What Does TVRD Do?

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, oral small molecule therapies that target STAT3, a key signaling pathway implicated in fibrosis, inflammation, and cancer. Founded with the mission of addressing significant unmet medical needs in fibrosis-driven diseases, Tvardi is pioneering a new approach to treating conditions like idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). The company's lead candidate, TTI-101, is an orally bioavailable small molecule designed to selectively inhibit STAT3 activation. Currently, TTI-101 is undergoing Phase 2 clinical trials for both IPF and HCC, representing a critical stage in its development. Tvardi's focus on oral administration provides a potential advantage over existing therapies, which often require intravenous delivery. The company's research and development efforts are centered in Sugar Land, Texas, where a team of scientists and clinicians are working to advance TTI-101 and expand the pipeline with additional STAT3-targeting therapies. Tvardi's strategy involves identifying and validating novel therapeutic targets within the STAT3 pathway, developing potent and selective small molecule inhibitors, and conducting rigorous preclinical and clinical studies to demonstrate safety and efficacy. The company aims to establish itself as a leader in the development of STAT3-targeted therapies for fibrosis-driven diseases, offering new hope for patients with limited treatment options.

What Products and Services Does TVRD Offer?

• Develop oral small molecule therapies targeting STAT3.
• Focus on treating fibrosis-driven diseases.
• Conduct Phase 2 clinical trials for lead candidate TTI-101 in IPF.
• Conduct Phase 2 clinical trials for lead candidate TTI-101 in HCC.
• Research and develop novel therapeutic targets within the STAT3 pathway.
• Develop potent and selective small molecule inhibitors.
• Conduct preclinical studies to demonstrate safety and efficacy.

How Does TVRD Make Money?

• Develop and commercialize novel therapies for fibrosis-driven diseases.
• Generate revenue through sales of approved therapies.
• Out-license or partner with larger pharmaceutical companies for development and commercialization.
• Seek funding through venture capital, public offerings, and grants.

What Industry Does TVRD Operate In?

Tvardi Therapeutics operates within the biotechnology industry, which is characterized by high innovation, long development timelines, and significant regulatory oversight. The company focuses on fibrosis-driven diseases, a market with substantial unmet needs and growing prevalence. The competitive landscape includes established pharmaceutical companies and other biotech firms developing therapies for IPF and HCC. The biotechnology industry is experiencing growth driven by advancements in genomics, personalized medicine, and targeted therapies. Tvardi's focus on STAT3 inhibition positions it within the targeted therapy segment, which is expected to grow as researchers gain a deeper understanding of disease mechanisms.

Who Are TVRD's Key Customers?

• Patients with idiopathic pulmonary fibrosis (IPF).
• Patients with hepatocellular carcinoma (HCC).
• Healthcare providers who treat patients with fibrosis-driven diseases.
• Pharmaceutical companies seeking to acquire or license novel therapies.

Company Profile

Tvardi Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sugar Land, US. The company is led by CEO Imran Alibhai. TVRD has traded publicly since 2014.

Tvardi Therapeutics's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.11 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Tvardi Therapeutics stands at -64.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -59.8%, showing how much profit it generates from its asset base. A current ratio of 2.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -93.0%, the inverse of the P/E and a quick read on earnings relative to price.

TVRD Valuation & Market Position

With a $17.2M market cap, Tvardi Therapeutics sits in the micro-cap segment of the market. Relative to its peer group, TVRD's quantitative score of 25/100 is below the peer average of 76/100.

Tvardi Therapeutics has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 61.0% below estimates on average.

Wall Street analysts project Tvardi Therapeutics revenue of about $0 for fiscal 2026, with EPS near $-2.50.

TVRD Financials

TVRD Latest News

TVRD Analyst Consensus

TVRD MoonshotScore

Common Questions About TVRD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources